62 results on '"Le Pen C"'
Search Results
2. Investigation of the barrier properties of silanes on cold rolled steel
3. Effect of bath concentration and curing time on the structure of non-functional thin organosilane layers on aluminium
4. T06.01.19 THE ECONOMIC COST AND HEALTH BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS IN THE EU5 COUNTRIES
5. The economic cost and health burden of non-alcoholic steatohepatitis in the EU5 countries
6. PGI27 THE BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN THE EU5 COUNTRIES
7. Étude FRANTALGIC – Intensification du traitement par opioïde chez les utilisateurs douloureux chroniques : analyse des données de remboursement de l’Assurance maladie
8. PHP182 - EXTERNAL REFERENCE PRICING: CONSEQUENCES OF FRENCH PRICE DECREASES ON INTERNATIONAL TURNOVER
9. Télémédecine et dépenses de santé – une modélisation économique évaluant l’impact d’une intervention en télémédecine dans trois pathologies chroniques : diabète de type 2, hypertension artérielle et cancer de la prostate
10. Cost-minimization study comparing simulect versus thymoglobulin in renal transplant induction
11. 1 - Silane films for the pre-treatment of aluminium: film formation mechanism and curing
12. P-05: Situation de la prescription des immunoglobulines antirabiques (RIG) en France : quantités, coûts et anticipation des ruptures de stock
13. PHP8 - A Long War Begins: Biosimilars Versus Patented Biologics – A Retrospective Analysis Of The Eu-5 And Japanese Erythropoetins Markets
14. PHP13 - To What Extent Can Biosimilars Compete with Brand Name Biologics? A EU-5 Granulocyte-Colony Stimulating Factors Markets Analysis
15. PHP12 - A Price Comparison Study of Recent Drugs in EU5, 2008-2012
16. PCN135 The Economic Value of Medical Progress, the Case of Cancer in France (1990-2010)
17. PHP75 Is Orphan Designation a Driver of Orphan Drug Pricing?
18. PHP9 Temporary Use Authorizations: The Economic and Clinical Future of Drugs Used in the French Compassionate Program
19. PCN170 PUBLIC REGULATION OF THE CANCER DRUGS MARKET IN FRENCH HOSPITALS
20. PHP30 PRIMARY CARE AND AVOIDABLE HOSPITALIZATIONS: A COMPARATIVE ANALYSIS BETWEEN FRANCE AND THE UK
21. PHP11 DOES PHARMACEUTICAL CONSUMPTION IMPROVE HEALTH CARE STATUS?
22. PSS39 PSORIASIS: AN EPIDEMIOLOGIC EVALUATION OF DISEASE BURDEN IN 590 PATIENTS
23. PSS1 VERTEPORFIN IN NEOVASCULAR AMD: REAL LIFE CONFIRMS CLINICAL TRIALS RESULTS
24. PMS87 IMPACT OF RHEUMATOID ARTHRITIS (RA) ON WORKING CONDITIONS AND INCOME
25. PMS62 INDIRECT COSTS OF RHEUMATOID ARTHRITIS AND THEIR DETERMINANTS
26. PSS25 COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS
27. PMS19 COST-EFFECTIVENESS OF USING ETANERCEPT AS FIRST LINE IN SEVERE AND HIGHLY ACTIVE RHEUMATOID ARTHRITIS (RA)
28. Efficacité de la contention lombaire souple par la ceinture de soutien Thuasne Lomba-Cross Activity dans le traitement de la lombalgie subaiguë
29. EC4 COST-EFFECTIVENESS AND COST-UTILITY OF RITUXIMAB MAINTENANCE THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN FRENCH SETTING
30. PIN33 THE COST OF ZOSTERAND POST-HERPETIC NEURALGIA TREATMENT IN FRANCE
31. PIN9 A COST-EFFECTIVENESS ANALYSIS OF A YEARLY FIBROSCAN® LIVER FIBROSIS ASSESSMENT COMPARED WITH A PERIODIC LIVER BIOPSY IN HEPATITIS C VIRUS (HCV) INFECTED INDIVIDUALS IN A FRENCH SETTING
32. PEY10 COST-EFFECTIVENESS OF TWO TREATMENT SEQUENCES IN GLAUCOMA TREATMENT: XALATAN®-XALACOM® VERSUS TRAVATAN®-DUOTRAV®
33. PCN30 ECONOMIC EVALUATION OF FOLFOX4 VERSUS FOLFOX7 WITH OXALIPLATIN STOP-AND-GO IN ADVANCED COLORECTAL CANCER PATIENTS
34. OA3 HOW DO PRESCRIBERS ACT WHEN A PRODUCT IS WITHDRAWN FROM THE MARKET? FIRST LESSONS FROM THE COX-2 INHIBITORS PATIENTS POST ROFECOXIB STUDY (CIPRES)
35. PEY20 IMPACT OF BEST AND WORST EYE VISUAL ACUITY ON VISION-SPECIFIC HEALTH-RELATED QUALITY OF LIFE AND UTILITY IN PATIENTS SUFFERING FROM AGE-RELATED MACULAR DEGENERATION
36. PEY14 IMPACT OF VISUAL ACUITY ON MEDICAL AND NON-MEDICAL COSTS IN PATIENTS SUFFERING FROM WET AGE-RELATED MACULAR DEGEN-ERATION IN FRANCE, GERMANY AND ITALY
37. PEY1 ANXIETY AND DEPRESSION IN WET AGE-RELATED MACULAR DEGENERATION (ARMD)
38. PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN FRANCE
39. PNL13 PROFILE OF PATIENTS SUFFERING FROM RESTLESS LEGS SYNDROME AND ESTIMATION OF THEIR ANNUAL COST IN AN AMBULATORY CARE SETTING, IN FRANCE
40. POS5 MEDICO-ECONOMIC EVALUATION OF VERTEBRAL FRACTURE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN
41. PHP4 PERSPECTIVE OF THE GENERIC MARKET IN FRANCE: 2004-2008
42. PAR5 MESSAGE: AN OBSERVATIONAL POST-LAUNCH STUDYTO ASSESS EFFECTIVENESS AND COST OF SUPLASYN® IN PATIENTS WITH KNEE OSTEOARTHRITIS
43. PAR4 THE COART STUDY: THE COST OF OSTEOARTHRITIS IN FRANCE BETWEEN 1991 AND 2002
44. HP5 WHAT HAPPENS WHEN A PHARMACEUTICAL PRODUCT IS REMOVED OUT OF REIMBURSEMENT?
45. PCV38: A COST AND COST-EFFECTIVENESS (CE) ANALYSIS OF ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORTRANDOLAPRIL IN THE TREATMENT OF POST INFARCTION IN THE US
46. PNM11 IMPACT OF DEEP BRAIN STIMULATION (DBS) OF THE SUBTHALAMIC NUCLEUS (STN) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND HEALTH CARE RESOURCE USE IN ADVANCED PARKINSONIAN PATIENTS
47. PIN1 PHARMACEUTICAL MANAGEMENT OF NEWLY HIV + DIAGNOSED PATIENTS: RESULTS FROM THE STAR (SCHEMAS THERAPEUTIQUESANTIRETROVIRAUX) COHORT
48. PCV24 THE MAHLER STUDY: DIFFERENCES IN RESOURCE USE FOR THE MANAGEMENT OF CHRONIC HEART FAILURE ACROSS 6 EUROPEAN COUNTRIES
49. PAE13 COST-EFFECTIVENESS ANALYSIS OF TIMOLOL LATANOPROST AND TRAVOPROST IN 3 EUROPEAN COUNTRIES: THE UK, GERMANY AND FRANCE
50. CV12 A COST-EFFECTIVENESS ANALYSIS OF ACE INHIBITOR TRANDOLAPRIL AS A PREVENTATIVE TREATMENT OF HEART-FAILURE PROGRESSION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.